Teva to Refund $1.2 Billion to Buyers Who Overpaid for Drug

Settlement ends fight over controversial pay-for-delay agreements.

comments Print
United States antitrust regulators have settled a long-running fight with Cephalon, now owned by Israel’s Teva Pharmaceuticals, over how it resolved a patent infringement lawsuit tied to wakefulness drug...